Johnson & Johnson MedTech Announces Labeling Amendment of LINX Reflux Management System in the U.S. to Include Patients With Barrett's Esophagus Experiencing Gastroesophageal Reflux Disease
August 08, 2024
August 08, 2024
NEW BRUNSWICK, New Jersey, Aug. 8 (TNSres) -- Ethicon, a Johnson and Johnson MedTech company, issued the following news release:
* * *
Labeling update for the LINX Reflux Management System will provide more patients relief from gastroesophageal reflux disease (GERD).
Amendment is based on study results that found LINX(TM) to be safe and effective at treating GERD in patients with Barrett's esophagus (BE).
* * *
CINCINNATI, OH Augus . . .
* * *
Labeling update for the LINX Reflux Management System will provide more patients relief from gastroesophageal reflux disease (GERD).
Amendment is based on study results that found LINX(TM) to be safe and effective at treating GERD in patients with Barrett's esophagus (BE).
* * *
CINCINNATI, OH Augus . . .